Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany

CANNANNEW REPORT

Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announces its financial results for the quarter ended June 30, 2021. These filings are available for review on the Company’s SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated. Summary of Key Financial Results 3 Months 3 Months 3 Months ended Jun ended Jun ended Mar Canadian dollars 30 2021 30 2020 31 2021 $ $ $ Revenues (‘000s) 2,803 1,670 2,837 Medical Cannabis 826 25 563 Gross profit before fair value adjustments (‘000s) 1,046 319 1,090 General and administrative costs (‘000s) 4,428 4,531 5,592 Net loss (‘000s) (4,796) (5,713) (5,494) Adjusted EBITDA (1) (‘000s) (3,850) (3,855) (4,019) Net loss per share (basic and diluted) (0.03) (0.05) (0.04) Weighted average shares outstanding (‘000s) 151,027 116,546 150,718 (1) Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization or in this case loss) is a non-International Financial Reporting Standards (“IFRS“) measure calculated as net loss before tax as reported under IFRS and adding back share-based compensation expense, transaction fees, unrealized gain on changes in fair value of biological assets, depreciation and non-recurring items. Refer to the “Non-IFRS Measures” note below for further information and the Company’s MD&A for a reconciliation. Key Operating Statistics 3 Months 3 Months 3 Months ended Jun ended Jun ended Mar 30 2021 30 2020 31 2021 Medical Cannabis Revenue generating countries (#) 4 1 4 Latin America (Units) 11,058 380 7,969 Europe (Grams) 42,890 N/A 11,080 Health Services Patient interactions (#) 32,984 19,151 32,331 Wellness Units (#) 3173 3,064 2,758 Management Commentary“In Q2, we continued to achieve strong results within our Medical Cannabis segment, reporting 47% sequential growth and margins of over 85% for the fourth consecutive…

Excerpt only …
READ MORE BELOW
Source : Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.